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The pharmacokinetics of oxiracetam and its degraded substance (4-hydroxy-2-oxo-1-
pyrrolidine acetic acid, HOPAA) after oral and intravenous administration in rats were stud-
ied using an established UPLC-MS/MS method. Three groups of rats after an overnight fasted
received 10 g/kg (n ¼ 6) oxiracetam suspensions orally, and 2 g/kg (n ¼ 6) normal or degraded
oxiracetam injections intravenously via a caudal tail vein, respectively. Before the pharmaco-
kinetic experiment, a simple safety evaluation testwas conducted on thedegraded oxiracetam
injections containing 16.16% HOPAA in mice. There was no mortality by a single intravenous
doseof 2 g/kg of degraded oxiracetam injectionswithin twoweeks, demonstrating thatHOPAA
was non-toxic in mice. Following intravenous administration of the normal injections, the
plasma concentration-time curves of oxiracetamandHOPAAboth showed a rapid elimination
phase. Thevalues of t1/2were 3.1± 1.5h for oxiracetamand0.8±0.2 h forHOPAA, and themean
residence times (MRT)were1.2±0.1hand0.8±0.1h, respectively.OxiracetamandHOPAAafter
intravenous administration of the degraded oxiracetam injections presented elimination pat-
terns similar to those observed in the normal injections. Oral pharmacokinetic results showed
that the Tmax was less than 1.5 h for the two analytes, and both had a longer t1/2 andMRT than
thoseof intravenous administration.Contents ofHOPAA in three groupswere calculatedbased
on AUC0et values of the two analytes. The quantitative change of HOPAA in vivo was also
evaluatedby comparing theplasmaconcentrationsofHOPAAandoxiracetamat the same time
for every group. Additionally, the values of absolute bioavailability of oxiracetam were about
8.0% and 7.4% calculated by the normal or degraded oxiracetam injections,whichwere far less
than the value of 75% reported in literature, indicating the necessity of further study.
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a cyclic hydroxy-amino butyric acid derivative, and is widely
applied in improving central nervous system disorders as a
cognition enhancer [1,2]. It has been found to improve
learning, memory and acquisition processes [3,4]. Recently,
there are also some domestic researches on oxiracetam.
Huang RY verified its effect on vascular dementia combined
with nimodipine, and Li JW et al. then confirmed its protective
effect on traumatic brain injury in rats [5,6].
HOPAA, 4-hydroxy-2-oxo-1-pyrrolidine acetic acid, is a
degraded substance of oxiracetam. Determined by high per-
formance liquid chromatography (HPLC) in our lab, the con-
tents of HOPAA were 0.5% and 0.04% for lab-made
oxiracetam injections and oxiracetam tablets, and 1.0% and
0.07% for the original commercial injections and tablets
(Korean Drug Co., Ltd), respectively. HOPAA was proved to be
the main degraded substance comparing with other related
substances, whose content had exceeded the impurity limit
(0.3%) according to our own product quality standard. So far,
there is no further research on it besides an examination in
formulations and a sensitive HPLC-MS/MS method for its
determination in rat plasma [7,8]. In order to verify whether
contents of HOPAA would increase and thus bring any un-
derlying danger to patients in vivo, a simple toxicity test in
mice was conducted to ensure the safety of HOPAA and the
degraded injections containing 16.16% HOPAA obtained
based on a violent hydrolysis reaction and the normal oxir-
acetam injections were used as the test and the reference
preparations, respectively. Then, the pharmacokinetic
experiment was developed to investigate the pharmacoki-
netics behaviors of oxiracetam and HOPAA in rats
simultaneously.A B C
Fig. 1 e Chemical structures of the: (A) oxiracetam, (B)
HOPAA and (C) piracetam.2. Materials and methods
2.1. Materials
Oxiracetam (99.7% pure, Fig. 1A) and piracetam (100.0% pure,
Fig. 1C) were both supplied by the National Institutes for Food
and Drug Control (Beijing, China). HOPAA (97.0% pure, Fig. 1B)
was purchased from Shenzhen Yasuo Sci-Tech Co., Ltd
(Shenzhen, China). Methanol and acetonitrile (HPLC grade)
were bought from Fisher Scientific (Pittsburgh, USA). Formic
acid was acquired from Dikma Reagent Company (Ohio, USA).
Oxiracetam injections (1 g/5 ml, purity of 99.50%) and oxir-
acetam tablets (800 mg) were both lab-made.
2.2. Toxicity test of oxiracetam injection after hydrolysis
reaction
HOPAA is the degradation product of oxiracetam in which
amino was instead by hydroxyl. 16.16%HOPAA solution in the
toxicity study was prepared by a destructive test of heating
the solution of oxiracetam injection in thewater bath for 120 h
under pH adjusted from 4.35 to 7.2 with 0.1 M sodium hy-
droxide solution. Then the oxiracetam injection after heatingwas regulated to the original pH 4.35 by 0.1 M phosphoric acid
solution, sterilized under 121 C for 15 min after packaging in
ampoules, and stored at 4 C before use.
40 Kunming mice male and female (20 ± 2 g), provided by
Shenyang Pharmaceutical University Animal Care and Use
Committee, were housed at the room temperature (25 ± 2 C)
and a relative humidity of 65 ± 5% under the natural light/dark
conditions for 1 week. Then, mice were fasted for 12 h prior to
the experiment. All mice were divided into two groups for the
experimental group and the control, and mice in each group
were divided evenly between male and female. Then the
experimental group was administered the degraded oxir-
acetam injections containing 16.16%HOPAA intravenously via
a caudal tail vein at a dose of 2 g/kg body weight calculating by
oxiracetam. Similarly, the control was administered in the
same way at the same dose level after conversion. Then all
animals were observed for any adverse clinical signs imme-
diately and restore their normal diet for the 2 weeks' obser-
vation period.
2.3. Pharmacokinetics study design
18 Sprague Dawley male rats weighed of 250 ± 10 g in this
pharmacokinetics experiment, were approved by animal
center of Shenyang Pharmaceutical University (Shenyang, P.R.
China). All animals were housed in a temperature- and
humidity-controlled environment, which was in accordance
with institutional guidelines and approved by Shenyang
Pharmaceutical University Animal Care and Use Committee.
The rats were fasted overnight with ad libitum access to water
prior to the experiment and divided into three groups
randomly (n ¼ 6). The oral suspensions of oxiracetam was
prepared by suspending the drug powder in 0.5% CMC-Na
with the concentration of 1 g/ml and orally administered at
a single dose of 10 g/kg. The normal oxiracetam injections and
degraded injections were intravenously administered at a
dose of 2 g/kg calculating by oxiracetam after conversion by
the tail vein. No any adverse effect was observed during the
whole experimental period.
Blood samples (about 300 ml) were collected into heparin-
ized tubes and were centrifuged at 3000 rpm for 10 min to
obtain the plasma. The blood sampleswere collected at 0 (pre-
dose), 0.17, 0.33, 0.50, 0.75, 1, 1.5, 2, 3, 5, 8, 10, 12, and 24 h after
oral administration and at 0 (pre-dose), 0.08, 0.17, 0.33, 0.50,
0.75, 1, 1.5, 3, 5, 8, 12, 24 h after intravenous administration via
Table 1 e Major pharmacokinetic parameters of
oxiracetam after oral administration of 10 g/kg and
intravenous administration of 2 g/kg normal or degraded
injections to rats (n ¼ 6).
Parameter Administration mode
Oral Intravenous
10 g/kg 2 g/kg (N.I) 2 g/kg (D.I)
Cmax (mg/ml) 365.7 ± 71.5 e e
tmax (h) 1.4 ± 0.6 e e
t1/2 (h) 7.0 ± 3.4 3.1 ± 1.5 2.3 ± 1.2
AUC0/t (mg/ml$h) 2832.3 ± 622.9 7085.0 ± 773.9 7607.1 ± 1121.3
MRT0et (h) 5.4 ± 0.9 1.2 ± 0.1 1.4 ± 0.3
Vd/F (L/kg) 24.5 ± 2.2 1.2 ± 0.6 0.9 ± 0.6
CL/F (L/h/kg) 2.8 ± 1.0 0.3 ± 0.0 0.3 ± 0.0
Note: All date are mean ± standard deviation (SD). N.I, normal in-
jections; D.I, degraded injections.
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centrifugation at 3000 rpm for 10min to obtain the plasma and
stored at 20 C before analysis.
2.4. Analysis of oxiracetam and HOPAA concentration
in the plasma
The oxiracetam and its related substance HOPAA in rat
plasma were analyzed by HPLC-MS/MS method [8].
A non-compartmental method was used in the pharma-
cokinetic analysis. Pharmacokinetic parameters, including
maximum plasma concentration (Cmax), time to reach Cmax
(Tmax), area under the curve (AUC), elimination half-life (t1/2),
Mean residence time (MRT), plasma clearance (CL) and the
apparent volume of distribution (Vd) were calculated using
DAS 2.1.1 pharmacokinetic software (Chinese Pharmacology
Society). The contents of HOPAA in three groups in vivo and
the absolute bioavailability value of oxiracetam were calcu-
lated by the following two equations:
Content% ¼ AUCHOPAA
AUCoxiracetm þAUCHOPAA  100% (A)
F% ¼ AUCoral
AUCiv:
 Doseiv:
Doseoral
 100% (B)
AUCHOPAA and AUCoxiracetam in Equation A were the values
of AUC0~t of HOPAA and oxiracetam at the same time and in
the same group. AUCoral and AUCiv in Equation B were the
values of AUC0et of oxiracetam after oral and intravenous
dosing, respectively. All of the pharmacokinetic parameters
were expressed as mean ± SD.Table 2 e Major pharmacokinetic parameters of HOPAA
after oral administration of 10 g/kg and intravenous
administration of 2 g/kg normal or degraded injections to
rats (n ¼ 6).
Parameter Administration mode
Oral Intravenous
10 g/kg 2 g/kg (N.I) 2 g/kg (D.I)
Cmax (mg/ml) 1.6 ± 0.6 e e
tmax (h) 1.3 ± 0.6 e e
t1/2 (h) 9.6 ± 4.9 0.8 ± 0.2 1.4 ± 0.5
AUC0/t (mg/ml$h) 9.8 ± 2.2 46.5 ± 2.8 570.8 ± 98.3
MRT0et (h) 4.3 ± 0.5 0.8 ± 0.1 0.8 ± 0.2
Vd/F (L/kg) 2.8 ± 0.8 0.2 ± 0.1 1.2 ± 0.3
CL/F (L/h/kg) 0.2 ± 0.1 0.2 ± 0.0 0.6 ± 0.1
Note: All date are mean ± standard deviation (SD). N.I, normal in-
jections; D.I, degraded injections.3. Results and discussion
3.1. Toxicity test of oxiracetam injection after hydrolysis
reaction
General pharmacology showed that oxiracetam has no
adverse effect on the nerves system, respiratory system and
cardiovascular system. Acute toxicity study revealed that the
LD50 values of oxiracetam in mice and rat were both not less
than 10 g/kg [1]. The fundamental purpose of this studywas to
verify the safety of HOPAA in oxiracetam injection, so an
appropriate dose of 2 g/kg was chosen for administration in
mice. The degraded oxiracetam injections containing 16.16%
HOPAA were prepared by heating the lab-made injections
under the condition of weak alkaline and tests proved that pH
of 7.2 was the best hydrolysis condition.
The immediate observation within 3 h after single intra-
venous administration showed that there were no significant
difference between two group mice in dieting, action and
mental state. All the mice survived to the 14 d of observation
period.
3.2. Pharmacokinetics study
In order to detect HOPAA accurately in plasma samples, a
higher dose of 10 g/kg for oral administration and 2 g/kg for
intravenous were used. The pharmacokinetic parameters ofoxiracetam and HOPAA after oral administration of oxir-
acetam suspensions and intravenous administration of
normal or degraded oxiracetam injections are presented in
Table 1 and Table 2, respectively. The mean plasma concen-
tration versus time profiles of oxiracetam and HOPAA in three
groups are shown in Figs. 2e4, respectively.
For intravenous administration of the normal oxiracetam
injections, the plasma concentrations of oxiracetam and
HOPAA both decreased rapidly. Mean values of t1/2 were
3.1 ± 1.5 h for oxiracetam and 0.8 ± 0.2 h for HOPAA, and the
mean residence times (MRT) of them were 1.2 ± 0.1 h and
0.8 ± 0.1 h, respectively. Parameters including t1/2 and MRT for
oxiracetam and HOPAA in two intravenous groups proved no
significant difference (P > 0.05), indicating that the two ana-
lytes after intravenous administration of the degraded in-
jections exhibited similar elimination patterns to those
observed in the normal injections. For oral administration,
oxiracetam and HOPAA reached the peak plasma concentra-
tion simultaneously at about 1.4 h, demonstrating that HOPAA
was absorbed as rapidly as oxiracetam. Overall, for both
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Fig. 2 e Concentration-time profile of oxiracetam and HOPAA in rat plasma after a single oral administration oxiracetam
suspensions at a dose of 10 g/kg (n ¼ 6).
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Fig. 3 e Concentration-time profile of oxiracetam and HOPAA in rat plasma after a single intravenous administration normal
oxiracetam injections at a dose of 2 g/kg (n ¼ 6).
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administration were longer than those of intravenous groups
clearly, which may due to that the drug absorption did not
occur and complete immediately because of the high dose.
However, the t1/2 values of 7.0 ± 3.4 h for oxiracetam in oral0
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Fig. 4 e Concentration-time profile of oxiracetam and HOPAA in
degraded oxiracetam injections at a dose of 2 g/kg (n ¼ 6).groups was similar to that of 8.5 ± 1.7 h in human [9] and a
little longer than the results reported by some domestic re-
searches in rats [10,11]. It may be explained by the relative
shorter sampling schedule of 12 h in their investigations,
which would lead to the inaccurate evaluation on t1/2.12 16 20 24
ime (h)
Oxiracetam
HOPAA
8 10 12
 (h)
rat plasma after a single intravenous administration
Table 3 e Contents of HOPAA for three administration
group in vitro and in vivo (n ¼ 6).
Administration mode
Oral Intravenous
10 g/kg 2 g/kg (N.I) 2 g/kg (D.I)
In vivo (%) 0.3 ± 0.1 0.7 ± 0.1 7.0 ± 0.9
In vitro (%) 0.04 0.54 16.16
Note: All date are mean ± standard deviation (SD). N.I, normal in-
jections; D.I, degraded injections.
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stance HOPAA was determined successfully in all groups. The
contents of HOPAA for the three groups in vivowere calculated
using the Equation A. Table 3 presented a comparison for the
percentage of HOPAA in oxiracetam in vivo and the contents of
it in formulations. Comparison results showed that the con-
tents of HOPAA in vivo in three groups versus the data in vitro
proved to be three different results completely. For the oral
group, content of HOPAA in vivo exceeded that in vitro by
approximately seven fold revealing that part of oxiracetam
may be transformed into HOPAAby hydrolysis reaction during
the oral absorption process in the gastrointestinal tract. For0.00
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Fig. 5 e Mean concentration ratios of HOPAA and oxiracetam a
(n ¼ 6), (B) normal oxiracetam injections (n ¼ 6) and (C) degradethe group administered normal oxiracetam injections, con-
tent of HOPAA in vivo was equal to that in pharmaceutical
formulations. However, for the other intravenous group,
content of HOPAA detected in vivowas only half of that in vitro,
which may be explained by the metabolism of HOPAA in vivo.
According to the structure of HOPAAwith two eOH, it is liable
to form phaseⅡmetabolism in vivo including glucuronidation,
acetylation and so on. Thus, contents of HOPAA in vivo and
in vitro have no linear correlation.
Additionally, the ratios of concentrations of HOPAA and
oxiracetam at the same time for the three groups were
calculated to investigate the quantitative changes of HOPAA
in vivo. Fig. 5 shows the mean plasma concentration ratios of
HOPAA and oxiracetam versus time profile for three groups.
For oral group, the ratio was decreased mildly at the range of
0.45%~0.29% within 10 h. For the normal oxiracetam group,
the ratio was decreased faster than oral group with a minor
fluctuation. And for the group administered degraded in-
jections, the ratio was decreased rapidly from 13.20% to 2.63%
within 12 h.
The mean AUC0et values of oxiracetam after oral dosing
were 2832.3 ± 622.9 mg h/ml. Similarly, themean AUC0-t values
of the two intravenous groupswere 7085.0 ± 773.9 mg h/ml and
7607.1 ± 1121.3 mg h/ml for the normal oxiracetam injections
and degraded injections, respectively. The absolute6 8 10 12
e (h)
 Oxiracetam suspensions
6 8
 (h)
Normal oxiracetam injections
9 12
 (h)
Degraded oxiracetam injections
t the same time for the: (A) oral oxiracetam suspensions
d oxiracetam injections (n ¼ 6).
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by the two intravenous groups, respectively, far less than that
of 75% in healthy volunteers [9]. It may be due to the species
differences fromhuman and rat, dosage discrepancy that 10 g/
kg orally administered to rat in our study and 2 g/kg used in
the previous literature.4. Conclusion
Toxicity test for degraded injection containing 16.16% HOPAA
conducted in this research demonstrated that it was non-toxic
in mice. Above all, this was the first time to investigate the
pharmacokinetics behaviors of oxiracetam and its degraded
substance HOPAA in rats simultaneously. HOPAA and oxir-
acetam were both absorbed rapidly in the gastrointestinal
tract in the oral group and exhibited a rapid elimination phase
in intravenous groups. The contents of HOPAA in vivo in three
groups appeared to be different results completely versus
those in vitro suggesting that there was no linear correlation
between the contents of HOPAA in vivo and vitro. Meanwhile,
the absolute bioavailability of oxiracetam in rat was estimated
to be about 8%, which was far less that of 75% evaluated in
human indicating the necessity of further development.
Finally, HOPAA, a main degraded substance of oxiracetam,
has been confirmed to be non-toxic and the further investi-
gation of its efficacy is under investigation in rats in our
laboratory.Acknowledgment
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